Bladder Cancer

FDA issues draft guidance for adjuvant trials in bladder cancer, renal cell carcinoma

October 02, 2020

"Currently, there is significant variability in the design, conduct, and analysis of clinical trials for adjuvant treatment of both kidney cancer and bladder cancer. This variability negatively affects our ability to interpret trial results," said Richard Pazdur, MD.